Abstracts tagged "Cohort Study"

Abstract Number: LB16 • ACR Convergence 2025
Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis
David Silverman¹, Timothy Barnes², Nnaemeka Odo², Jared Silver³, Lisa Le², Amy Edgecomb⁴ and Hitesh Patel⁵, ¹Rheumatology Department, Kaiser Permanente Colorado Medical Group, Denver, Colorado, ²Value and Evidence Solutions, Optum Life Sciences, Eden Prairie, Minnesota, ³Clinical Development, Amgen, Thousand Oaks, California, ⁴Anti-infectives and Respiratory, GSK, Philadelphia, Pennsylvania, ⁵US Medical Affairs, GSK, Durham, North Carolina
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic diseases characterized by persistent eosinophilia and tissue infiltration, resulting in end-organ dysfunction…
Abstract Number: 2456 • ACR Convergence 2025
Predictors of Real-World Remission in Patients with SLE Initiating Belimumab in the USA
Aarat M Patel¹, Renee L. Gennarelli², Temitope Bello², Ali Bonakdar² and Karen Worley³, ¹GSK, US Medical Affairs, Durham, NC, ²Cencora, Real-World Evidence, Conshohocken, PA, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA
Background/Purpose: The Definition Of Remission in SLE (DORIS) criteria were developed to align SLE remission definitions.1,2 Post hoc analyses of clinical trial data demonstrated that…
Abstract Number: 2232 • ACR Convergence 2025
Risk factors for hospitalizations in a large, contemporary rheumatoid arthritis patient cohort
Argyro Lazarini¹, Konstantinos Thomas², EVRIPIDIS KALTSONOUDIS³, Paraskevi V Voulgari⁴, Alexandros Drosos⁵, Argyro Repa⁶, Ainour Molla ismail Sali⁶, Prodromos Sidiropoulos⁶, Kalliopi Fragkiadaki¹, Maria Tektonidou⁷, Petros Sfikakis⁸, Panagiota Tsatsani⁹, Sousana Gazi⁹, Evangelia Argyriou¹⁰, Kyriaki Boki¹⁰, Pelagia Katsimpri¹, Dimitrios Boumpas¹, Gerasimos Evangelatos¹¹, Alexios Iliopoulos¹², Konstantina Karagianni¹³, Lazaros Sakkas¹³, Konstantinos Melissaropoulos¹⁴, Panagiotis Georgiou¹⁴, Eleftheria Grika¹, PANAYIOTIS VLACHOYIANNOPOULOS¹, Theodoros Dimitroulas¹⁵, Alexandros Garyfallos¹⁶, Konstantinos Georganas¹⁷, Periklis Vounotrypidis¹⁸, Konstantinos Ntellis¹⁹, Georgios Kitas²⁰ and Dimitrios Vassilopoulos²¹, ¹Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, ²Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, ³Rheumatology Clinic, University of Ioannina, IOANNINA, Ioannina, Greece, ⁴Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Ioannina, Greece, ⁵Rheumatology Clinic, University of Ioannina, Ioannina, Greece, ⁶Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece, ⁷National and Kapodistrian University of Athens, Athens, Greece, ⁸NKUA - SCHOOL OF MEDICINE, Athens, Greece, ⁹Rheumatology Unit, KAT Hospital, Athens, Greece, ¹⁰Rheumatology Unit, Sismanoglio Hospital, Athens, Greece, ¹¹Third Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria Hospital, Athens, Attiki, Greece, ¹²⁴¹⁷ Army Share Fund Hospital (NIMTS), Department of Rheumatology, Athens, Greece, ZOGRAFOU, Greece, ¹³Department of Rheumatology, University of Thessaly, Larissa, Greece, ¹⁴Rheumatology Unit, Agios Andreas Hospital, Patras, Greece, ¹⁵Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, Thessaloniki, Greece, Thessaloniki, Greece, ¹⁶⁴th Department of Medicine, Aristotle University, Thessaloniki, Greece, ¹⁷Private office, Athens, ¹⁸Private office, Thessaloniki, Greece, ¹⁹Private office, Kalamata, Greece, ²⁰Hygeia Hospital, Athens, Greece, ²¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Clinical Immunology-Rheumatology Unit, ²nd Department of Medicine and Laboratory, Athens, Greece, Athens, Greece
Background/Purpose: There are limited data regarding the recent trends and risk factors for hospitalization in patients with rheumatoid arthritis (RA). Our aim was to estimate…
Abstract Number: 1965 • ACR Convergence 2025
Two-Year Outcomes of Microwave Ablation for Recurrent Monoarthritis with Synovial Hypertrophy Resistant to Medical Treatment: Expanded Cohort and Long-Term Follow-Up Results
Rabia Deniz¹, Tevfik Güzelbey², İlhan Nahit Mutlu², Kübra Kalkan³, Özgür Kılıçkesmez² and Cemal Bes⁴, ¹University of Health Sciences Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ²University of Health Sciences Başakşehir Çam and Sakura City Hospital, Department of Radiology, Istanbul, Turkey, ³University of Health Sciences Başakşehir Çam and Sakura City Hospital, Department of Rheumatology, Istanbul, Turkey, ⁴University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey
Background/Purpose: Recurrent monoarthritis (RM) is a significant therapeutic challenge in rheumatology, often persisting despite NSAIDs, corticosteroids (CS), DMARDs, and biologic therapies. Local interventions like intra-articular…
Abstract Number: 1634 • ACR Convergence 2025
Association of Systemic Lupus Erythematosus With Incident Heart Failure Requiring Hospitalization
Chun-Yu Lin, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan (Republic of China)
Background/Purpose: Cardiovascular complications are increasingly recognized as a significant cause of late mortality in patients with systemic lupus erythematosus (SLE). Although coronary heart disease risk…
Abstract Number: 1439 • ACR Convergence 2025
Bimekizumab in Psoriatic Arthritis. A real-world prospective study. Comparison of its efficacy in bDMARD-naive and IL-17A-experienced patients
Vassiliki Poulia¹, Eleni Sampatakaki², Dimitrios Katsifis-Nezis³, Maria Pappa³, Evangelia Mole⁴, Sousana Gazi⁴, Elpida Skouvaklidou⁵, Nikolaos Kougkas⁵, Maria Polyzou⁶, Loukia Koutsogeorgopoulou⁶, Ioannis Xynogalas⁷, Anastasios Karamanakos⁷, Konstantinos D Vassilakis¹, Evangelos Papadimitriou⁸, Charalampos Papagoras⁸, Gerasimos Evangelatos⁹, Nafsika Gerolymatou¹⁰, Paraskevi V Voulgari¹⁰ and George E Fragoulis¹, ¹First Department of Propedeutic and Internal Medicine, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ²Joint Academic Rheumatology Program, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, ⁴th Department of Internal Medicine, Athens, Greece, Athens, Attiki, Greece, ³Rheumatology and Clinical Immunology Unit, ⁴th Department of Internal Medicine, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ⁴Rheumatology department, KAT General Hospital of Attica, Athens, Attiki, Greece, ⁵⁴th Department of Internal Medicine, Aristotle University, Thessaloniki, Thessaloniki, Greece, ⁶Department of Pathophysiology, Joint Academic Rheumatology program, National and Kapodistrian University of Athens, Athens, Attiki, Greece, ⁷Department of Rheumatology, Evangelismos General Hospital, Athens, Attiki, Greece, ⁸First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Evros, Greece, ⁹Third Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria Hospital, Athens, Attiki, Greece, ¹⁰Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Ioannina, Greece
Background/Purpose: Bimekizumab, a dual IL-17 A and F blocker, has recently been added in the therapeutic rheumatologist’s armamentarium of PsA, but real-world evidence is lacking.…
Abstract Number: 1146 • ACR Convergence 2025
Association of Walking Volume and Intensity With Incident Gout: A Population-based Cohort Study
Ziying Wu¹, Ying Hu², Hongyi He³, Yuqing Zhang⁴, Nicola Dalbeth⁵, Junqing xie⁶, Yilun Wang⁷, Chao Zeng⁷, Guanghua Lei⁷ and Jie Wei⁷, ¹Xiangya Hospital, Central South University, Chang Sha, China (People's Republic), ²Xiangya School of Public Health Central South University, changsha, China (People's Republic), ³Xiangya Hospital Central South University, Changsha, China (People's Republic), ⁴Massachusetts General Hospital, Harvard Medical School, Boston, ⁵University of Auckland, Auckland, New Zealand, ⁶University of Oxford, Oxford, ⁷Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic)
Background/Purpose: Previous studies have reported that walking is associated with a lower risk of several metabolic diseases; however, evidence of its association with gout, a…
Abstract Number: 0612 • ACR Convergence 2025
Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
Fadi Kharouf¹, JuanPablo Diaz Martinez², Pankti Mehta³, Dafna D. Gladman⁴, Laura Whitall Garcia⁵ and Zahi Touma⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarials, particularly hydroxychloroquine, are a cornerstone of systemic lupus erythematosus (SLE) management, with well-established benefits including reduced disease activity, prevention of flares, and mitigation…
Abstract Number: 0453 • ACR Convergence 2025
Safety of DMARDs in Rheumatoid Arthritis: A Nationwide Study of ILD Risk and Outcomes in RA-ILD
kyung-Ann Lee¹, Bora Lee², Hyun-Sook Kim³ and Se Hee Kim⁴, ¹Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea, ²Chosun University, GwangJu, Republic of Korea, ³Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea, ⁴Kyung Hee University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a potentially life-threatening extra-articular manifestation of RA. The comparative safety of disease-modifying antirheumatic drugs (DMARDs) in RA…
Abstract Number: 0209 • ACR Convergence 2025
A Retrospective Safety Analysis based on Platelets in Arthrocentesis and Joint injections in Cancer Patients
Yuanteng Li¹, Cheuk Leung², Heather Lin², Angeles Lopez-Olivio³ and Jean Tayar³, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson Cancer Center, Houston, ³The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Arthrocentesis and joint injections are commonly performed to diagnose and to treat rheumatic conditions such as crystal-induced arthritis, septic arthritis, and inflammatory arthritis. While…
Abstract Number: 2703 • ACR Convergence 2025
Longitudinal Changes on Cranial Magnetic Resonance Imaging in Relapsing Giant Cell Arteritis
Ruoheng Zeng¹, Ryan Rebello², Konstanze Guggenberger³, Joshua Baker⁴, Shubhasree Banerjee⁴, Robert Kurtz⁴, Naomi Amudala⁴, Peter Merkel⁴ and Rennie Rhee⁴, ¹University of Pennsylvania School of Medicine, Philadelphia, PA, ²St. Joseph’s Hospital at McMaster University, Hamilton, ON, Canada, ³University Hospital of Wuerzburg, Wuerzburg, Germany, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is a need for better tools to monitor disease activity in giant cell arteritis (GCA). Prior studies demonstrated that vascular enhancement on cranial…
Abstract Number: 2453 • ACR Convergence 2025
Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE
Maral DerSarkissian¹, Yan Chen¹, Ariel Chao¹, Shumin Rui¹, Bronwyn Moore², Karen Worley³, Daniel Moldaver⁴, Jeffrey J. Ellis³ and Aarat M Patel⁵, ¹Analysis Group, Los Angeles, CA, ²Analysis Group, Montreal, QC, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ⁵GSK, US Medical Affairs, Durham, NC
Background/Purpose: LN develops in ~40% of patients with SLE and is associated with increased risk of morbidity, including end-stage kidney disease, and mortality. Belimumab, a…
Abstract Number: 2118 • ACR Convergence 2025
Risks of Fracture in Current and Previous Anticonvulsant Users, An Observational Study
Grace Hyeyeon Lee¹, Hamzah Amin² and marwan Bukhari¹, ¹University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom, ²Lancaster University, Lancaster, United Kingdom
Background/Purpose: Anticonvulsants are commonly used to manage neurological and psychiatric disorders such as epilepsy, migraines and bipolar disorder. These medications are often prescribed long-term, and…
Abstract Number: 1960 • ACR Convergence 2025
Item Response Theory to Develop an Ultrasound Composite Score for Knee Osteoarthritis Assessment
Liubov Arbeeva¹, Carolina Alvarez², Jonathan Samuels³, Janice Lin⁴, Minna Kohler⁵, Catherine Bakewell⁶, Todd Schwartz⁷ and Amanda Nelson⁸, ¹University of North Carolina, Chapel Hill, Carrboro, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³NYU Langone, Rye Brook, NY, ⁴Stanford University, Palo Alto, CA, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Intermountain Healthcare, Salt Lake City, UT, ⁷University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁸University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Semi-quantitative scoring systems have long been used for radiographic findings in osteoarthritis (OA), but limited work has utilized ultrasound (US). The aim of this…
Abstract Number: 1631 • ACR Convergence 2025
New Arterial Damage in Takayasu’s Arteritis
Tanaz Kermani¹, Sema Kaymaz-Tahra², Aysegul Avcu³, Fatma Alibaz-Oner⁴, Haner Direskeneli³ and Peter Merkel⁵, ¹University of California Los Angeles, Santa Monica, CA, ²Bahcesehir University Faculty of Medicine Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey, ³Marmara University, Istanbul, Turkey, ⁴MARMARA UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DIVISION OF RHEUMATOLOGY, Istanbul, Turkey, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Damage is one of the consequences of disease and is often considered irreversible. This study aimed to evaluate new arterial damage in Takayasu’s arteritis…

1
2
3
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].